Centocor ATTRACT T22 Study
- Date:
- 1996-2003
- Reference:
- SA/KET/A/1/6
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises records relating to the Centocor, and Kennedy Institute led C0168T22 study titled "A Placebo Controlled Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment, “or 'ATTRACT' study.
The study, led by principal investigator Ravinder Maini and sponsored by Centocor, aimed to evaluate in a placebo-controlled, double-blinded, randomised study the effectiveness of cA2 in reducing disease activity, joint damage and disability in patients with active rheumatoid arthritis despite methotrexate treatment. The study also aimed to evaluate the safety profile of cA2. The study involved 428 patients who participated for 54 weeks in multiple clinical sites in North America and Europe (including in London at the Charing Cross and Hammersmith Hospitals). The study data showed that Infliximab (cA2) in combination with methotrexate significantly prevents structural damage in comparison to methotrexate alone.
See SA/KET/A/2 for further Centocor research collaboration papers.